Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 8759267, 5 pages
http://dx.doi.org/10.1155/2016/8759267
Research Article

Necessity of Microdissecting Different Tumor Components in Pulmonary Tumor Pyrosequencing

Department of Pathology, Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL 33612, USA

Received 15 February 2016; Revised 20 June 2016; Accepted 25 July 2016

Academic Editor: Urzsula Demkow

Copyright © 2016 Dahui Qin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. R. Chowdhuri, L. Xi, T. H.-T. Pham et al., “EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection,” Modern Pathology, vol. 25, no. 4, pp. 548–555, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Z. Rosenberg, M. D. Armani, P. A. Fetsch et al., “High-throughput microdissection for next-generation sequencing,” PLoS ONE, vol. 11, no. 3, Article ID e0151775, 2016. View at Publisher · View at Google Scholar
  3. M. Ronaghi, S. Karamohamed, B. Pettersson, M. Uhlén, and P. Nyrén, “Real-time DNA sequencing using detection of pyrophosphate release,” Analytical Biochemistry, vol. 242, no. 1, pp. 84–89, 1996. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Ronaghi, M. Uhlén, and P. Nyrén, “A sequencing method based on real-time pyrophosphate,” Science, vol. 281, no. 5375, pp. 363–365, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Dufort, M.-J. Richard, and F. de Fraipont, “Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues,” Analytical Biochemistry, vol. 391, no. 2, pp. 166–168, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. R. A. Lilenbaum and L. A. Horn, “Management of EGFR mutation-positive non-small cell lung cancer,” Journal of the National Comprehensive Cancer Network, vol. 14, no. 5, supplement, pp. 672–674, 2016. View at Google Scholar
  7. D. S. Ettinger, D. E. Wood, W. Akerley et al., “NCCN guidelines insights: non-small cell lung cancer, version 4. 2016,” Journal of the National Comprehensive Cancer Network, vol. 14, no. 3, pp. 255–264, 2016. View at Google Scholar
  8. W. D. Travis, E. Brambilla, M. Noguchi et al., “International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma,” Journal of Thoracic Oncology, vol. 6, no. 2, pp. 244–285, 2011. View at Publisher · View at Google Scholar
  9. Qiagen, EGFR Pyro Handbook, Qiagen, 2010.
  10. Qiagen, PyroMark KRAS v2.0 Handbook, March 2010.
  11. Qiagen, RAF Pyro Handbook, September 2010.
  12. G. H. Heppner, “Tumor heterogeneity,” Cancer Research, vol. 44, no. 6, pp. 2259–2265, 1984. View at Google Scholar · View at Scopus
  13. L. I. Shlush and D. Hershkovitz, “Clonal evolution models of tumor heterogeneity,” American Society of Clinical Oncology Educational Book, pp. e662–e665, 2015. View at Publisher · View at Google Scholar